Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 3/20 | 0.51 |
| ▸ | LAP3 | P28838 | 1/20 | 0.51 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 5/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.42 |
| ▸ | IL1RN | P18510 | 1/20 | 0.42 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.42 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13538055 | 0.92 | LTA4H (0.60) | RENLTA4HLAP3IL1RNERAP2 | |
| SCHEMBL469826 | 0.89 | LAP3 (0.47) | RENLTA4HLAP3CSNK1E | |
| SCHEMBL27724013 | 0.89 | LAP3 (0.47) | RENLTA4HLAP3CSNK1E | |
| Hydrochloric Acid SCHEMBL3092868 | 0.88 | LAP3 (0.46) | RENLTA4HLAP3CSNK1E | |
| SCHEMBL14390649 | 0.86 | REN (0.45) | RENLTA4HLAP3ITGB3ITGA2B | |
| SCHEMBL25873498 | 0.82 | LTA4H (0.54) | LTA4HLAP3L3MBTL1 | |
| SCHEMBL13307522 | 0.78 | CTSB (0.51) | LTA4HLAP3CSNK1E | |
| SCHEMBL18081540 | 0.76 | LTA4H (0.58) | RENLTA4HLAP3ITGB3ITGA2B | |
| SCHEMBL24066657 | 0.75 | PSEN1 (0.57) | REN | |
| SCHEMBL13538057 | 0.75 | PSEN1 (0.57) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7649015-B2 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-20070190523-A1 | Method and compositions for identifying anti-hiv therapeutic compounds | GILEAD SCIENCES, INC. | 2007-08-16 | — | — | US | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | REN 3013/4885LTA4H 1533/4885LAP3 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.